Open AccessEffects of Single Intravenous Administration of Urapidil and Diltiazem in Patients with Nonfixed Pulmonary Hypertension Secondary to Chronic Obstructive Lung Disease
Author(s) -
F. Späh,
R Matthew Kottman,
U Schmidt
Publication year - 1994
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/00005344-199404000-00001
Subject(s) - diltiazem , urapidil , medicine , pulmonary hypertension , pulmonary artery , blood pressure , anesthesia , pulmonary wedge pressure , cardiology , heart rate , calcium
In patients with chronic obstructive lung disease (COLD), pulmonary hypertension (PH) often develops in addition over the course of years. In this study, the acute effects of urapidil and diltiazem in patients with mild PH secondary to COLD were investigated. Eighteen male and 2 female patients, aged 42-78 years, received in randomized, single-blind fashion single intravenous (i.v.) doses of either urapidil (35-50 mg, n = 10) or diltiazem (25 mg, n = 10). Mean pulmonary artery pressure (MPAP), pulmonary wedge pressure (PWP), mean arterial blood pressure (BP) (MAP), and arterial and central venous blood gases were determined at rest and during exercise (starting with 25 W with increases in 25-W steps) before and after drug administration. Urapidil caused a significant reduction in MPAP (from 19 +/- 7 to 15 +/- 4 mm Hg, p < 0.01), PWP (from 9 +/- 3 to 7 +/- 2 mm Hg, p < 0.05), but not significantly in MAP at rest, whereas with diltiazem only MAP was decreased (from 103 +/- 14 to 98 +/- 12 mm Hg, p < 0.05) and MPAP and PWP were not significantly increased.(ABSTRACT TRUNCATED AT 250 WORDS)